Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based study

BACKGROUND: Despite approval of azacitidine in 2004 and decitabine in 2006 in the US for chronic myelomonocytic leukemia (CMML), overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS: We selected older adults (age ≥66 years) diagnosed with CMML during 2001–2011 f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Zeidan, Amer M., Hu, Xin, Long, Jessica B., Wang, Rong, Ma, Xiaomei, Podoltsev, Nikolai, Huntington, Scott F., Gore, Steven D., Davidoff, Amy J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540984/
https://ncbi.nlm.nih.gov/pubmed/28621841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30814
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados